Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205046 · ClinicalTrials.gov registry record · Phase 1
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
A Phase 1 study, sponsored by Acerta Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03205046 is a Phase 1 study that was terminated before completion, run by Acerta Pharma. The registered enrollment target is 25 participants.
The verdict
NCT03205046, a Phase 1 study, was terminated before completion, sponsored by Acerta Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
Interventions
- DRUG acalabrutinib
- DRUG vistusertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205046
The ClinicalTrials.gov registry entry for NCT03205046 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which acalabrutinib is the first listed.
NCT03205046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03205046 about?
NCT03205046 is a clinical study titled "A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies". This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
What is the current status of trial NCT03205046?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-06-29. Estimated completion is 2019-11-20.
What interventions are being tested in trial NCT03205046?
The interventions under investigation include: acalabrutinib (DRUG), vistusertib (DRUG).
Who is sponsoring clinical trial NCT03205046?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.